NEW YORK, March 3 (GenomeWeb News) - LifeSpan BioSciences and Pfizer will co-develop an automated tissue pathology-analysis system for use in preclinical studies, the companies said today.
"The primary goal is to develop a product that Pfizer will use in their research," said Joe Brown, LifeSpan president and CEO.
He said the company would not yet disclose whether the product would be available on the general market, and declined to disclose financial terms of the deal. However, he said that Pfizer would be providing financial support for the project.
Based on LifeSpan's Alias system, the product will use "enhanced image capture and artificial intelligence analysis software to evaluate stained tissue specimens for quality and tissue abnormalities," the companies said.